Topics

IASLC 2019 Small Cell Lung Cancer Meeting focuses on immunotherapy and patient perspective

19:38 EDT 29 Mar 2019 | News-Medical.net

While non-small cell lung cancer is the more common form of lung cancer and attracts the lion's share of the research funding, recent developments in small cell lung cancer may be shifting that slightly.

Original Article: IASLC 2019 Small Cell Lung Cancer Meeting focuses on immunotherapy and patient perspective

NEXT ARTICLE

More From BioPortfolio on "IASLC 2019 Small Cell Lung Cancer Meeting focuses on immunotherapy and patient perspective"

Quick Search

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...